Glenmark Pharmaceuticals Ltd News

3 bullish stocks to track: Glenmark Pharma, Karur Vysya Bank and Go Digit

Choice Broking analyst Sachin Gupta has recommended three stocks to buy today in cash: Glenmark Pharma, Go Digit and Karur Vysya Bank.

Glenmark launches new pump packs for OTC adapalene gel in US market

New 15 g and 45 g packs target the US OTC dermatology market, where the comparable Differin gel segment recorded $45.8 million in annual sales

Pharma stocks zoom: Laurus Labs, Aurobindo hit new highs in trade

The BSE Healthcare index rallied over 1% in Monday's trade. Thus far in the financial year 2026-27, it outperformed the market by soaring 25%, against a near 4% rise in the BSE Sensex.

Glenmark expands US injectables portfolio with Calcium Gluconate launch

The product has been launched in 1,000 mg/10 mL and 5,000 mg/50 mL single-dose vials, along with a 10,000 mg/100 mL pharmacy bulk package

Glenmark receives US FDA approval for Fluticasone Propionate Nasal Spray

Glenmark's Fluticasone Propionate Nasal Spray is bioequivalent and therapeutically equivalent to Flonase Nasal Spray of Haleon US Holdings LLC

Stocks to watch: Tata Motors, Glenmark Pharma, IRCTC, Senco Gold, BEML

Tata Motors, Petronet LNG, Apollo Hospitals, IRCTC among companies set to announce Q1FY27 results today.

Glenmark Pharmaceuticals Q1 result: PAT at ₹482.83 cr, revenue at ₹4,018 cr

Glenmark Pharmaceuticals on Friday reported a multi-fold increase in consolidated profit after tax at Rs 482.83 crore in the first quarter ended June 30, 2026, on the back of strong revenue growth and low base effect. The company had posted a consolidated profit after tax (PAT) of Rs 46.97 crore in the corresponding quarter last fiscal, Glenmark Pharmaceuticals said in a regulatory filing. In the year-ago quarter, the company had an exceptional item outgo of Rs 323.23 crore. Consolidated total revenue from operations in the first quarter this fiscal stood at Rs 4,018.48 crore as compared to Rs 3,264.44 crore in the same period a year ago, the filing said. Total expenses in the quarter under review were higher at Rs 3,440.86 crore as compared to Rs 2,872.07 crore, the company said. "We have started FY2027 with broad-based growth across our key markets, reflecting strong execution and the resilience of our business. "India continued to outperform the market, North America delivered

Stocks to buy: TVS Motor among 3 stock ideas from Ajit Mishra; here's why

Technically, the Nifty has reclaimed the immediate resistance zone formed by the 20-day and 100-day DEMA, indicating an improvement in the near-term technical setup.

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Glenmark Pharma jumps over 2% on launch of Olanzapine single-dose vial

Glenmark Pharma stock advanced over 2% in Monday's intra-day trade, after the company's US arm announced the launch of Olanzapine single-dose vial.

Glenmark launches generic schizophrenia, bipolar disorder drug in US

Glenmark Pharmaceuticals on Monday announced the launch of the generic version of Olanzapine injection, indicated for treatment of schizophrenia and bipolar disorder, in the US. The company's arm Glenmark Pharmaceuticals Inc, USA has launched Olanzapine for injection of strength 10 mg/vial, single-dose vial, Glenmark said in a regulatory filing. The company's Olanzapine for injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa intramuscular injection 10 mg/vial, of Cheplapharm Registration GmbH, it added. "The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel," Glenmark President & Business Head, North America, Marc Kikuchi said. Citing IQVIA sales data for the 12-month period ended May 2026, Glenmark said the Zyprexa intramuscular injection market achieved annual sales of approximately USD 25.4 million.

Nifty Pharma index up 2%; Dr Reddy's, Ajanta, Ipca, Cipla surge up to 5%

In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.

Glenmark launches Lacosamide injection in US, targets $15.2 million market

Company's Lacosamide Injection, available in single-dose vials, is a generic version of UCB's Vimpat; reference drug recorded annual sales of $15.2 million

Stocks to watch today: Bosch, ABCL, Whirlpool India, Jubilant Foodworks

Stocks to Watch today, May 21, 2026: Bosch, Whirlpool of India, Aditya Birla Capital, and Reliance Industries are some of the key stocks to watch today